POZEN Logo
Print Page   Close Window

Press Release

POZEN to Present at the BMO 6th Annual Investor Conference - Focus on Healthcare

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 30, 2006--POZEN Inc. (NASDAQ: POZN) announced today that William L. Hodges, the company's chief financial officer, will present at BMO's 6th Annual Investor Conference on Thursday, December 7, 2006 at 11:00 a.m. (EST) at the Millennium Broadway Hotel in New York City. Mr. Hodges' presentation will be webcast and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima(TM) combining sumatriptan, formulated with RT technology, and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of the proton pump inhibitor esomeprazole magnesium with naproxen in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

CONTACT: POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Fran Barsky, 919-913-1044
Director, Investor Relations

SOURCE: POZEN Inc.